PlainPharmaWatch

CMS Open Payments · Program Year 2024

Boehringer Ingelheim Pharma GmbH & Co.KG

Boehringer Ingelheim Pharma GmbH & Co.KG reported $2,366,176.43 across General Payments, Research, and Ownership to 15 physicians and teaching hospitals across 363 transactions.

See the rankings → How this is sourced
$2.4M Top quartile payer
All-tracks total
363 Above-median volume
Transactions
15 Below-median reach
Recipients
−$50.7K
General Payments vs PY2023

Boehringer Ingelheim Pharma GmbH & Co.KG reported $2,366,176.43 across all CMS Open Payments tracks (General + Research + Ownership) to 15 physicians and teaching hospitals in Program Year 2024 - ranking #413 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $27,706.38, averaging $157.7K per recipient.

How Boehringer Ingelheim Pharma GmbH & Co.KG's $2.4M all-tracks total breaks down

Boehringer Ingelheim Pharma GmbH & Co.KG's payment reach score

Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.

Overall reach score

F

23/100

Total payments

F

32/100

Transaction volume

F

13/100

Physician reach

F

10/100

Payment type diversity

F

37/100

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the publisher.

CMS Sunshine Act warrant

Manufacturer boehringer-ingelheim-pharma-gmbh-co-kg Boehringer Ingelheim Pharma GmbH & Co.KG

$2.4M · #413/1,925 · 0.0% industry · PY2024

  • TOT $2.4M
  • RANK #413
  • SHARE 0.0%
  • TXN 363
  • RCP 15
  • CAT 3
  • GEN $27.7K
  • ΔGEN −$50.7K
  • TOP1 37.0%
  • PY 2024

Volume peers

Nearest volume peer: Axogen ($2.4M)

Boehringer Ingelheim Pharma …$2.4MAxogen$2.4MPotrero Medical, Inc.$2.4MIronwood Pharmaceuticals, Inc$2.4MRecordati_rare_diseases_inc.$2.3M
All-tracks payment totals near Boehringer Ingelheim Pharma GmbH & Co.KG (CMS Open Payments PY2024)

Boehringer Ingelheim Pharma GmbH & Co.KG sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

Release-over-release change

General Payments changed from PY2023 to PY2024

Boehringer Ingelheim Pharma GmbH & Co.KG's CMS-reported General Payments decreased by $50.7K (−64.7%) from PY2023 to PY2024.

How this year-over-year comparison is scoped

The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.

CMS source labels for this exact identifier: PY2022: BOEHRINGER INGELHEIM PHARMA GMBH & CO.KGPY2023: BOEHRINGER INGELHEIM PHARMA GMBH & CO.KGPY2024: Boehringer Ingelheim Pharma GmbH & Co.KG. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$78.4KPY2024$27.7K
PY2023
$78,416.46
PY2024
$27,706.38

What the Data Shows for Boehringer Ingelheim Pharma GmbH & Co.KG

The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For Boehringer Ingelheim Pharma GmbH & Co.KG, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.

Of the 3 general-payment categories charted below, "Travel and Lodging" is the largest at $15.5K across 4 transactions, 55.8% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).

General Payment Breakdown by Type

"Travel and Lodging" leads Boehringer Ingelheim Pharma GmbH & Co.KG's 3-category general-payment breakdown at $15.5K, 55.8% of the reported total.

How Boehringer Ingelheim Pharma GmbH & Co.KG divides its payments

General-payment categories, ordered by reported total

1. Travel and Lodging$15.5K2. Compensation for Services…$12.0K3. Food and Beverage$275.56
Payment Type Amount Transactions
Travel and Lodging $15.5K 4
Compensation for Services Other Than Consulting $12.0K 3
Food and Beverage $275.56 8

Recipient Concentration in General Payments

The five largest recipient relationships account for $27,706.38 (100.0%) of $27,706.38 in this company's General Payments records across 4 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Boehringer Ingelheim Pharma GmbH & Co.KG

The five named recipients with the highest reported General Payments from this company

Frederick G Moeller$10.2KPatricia Mucci Lo Russo$7.3KGyongyi Szabo$5.2KBernd Schnabl$4.9K
  1. 1

    Frederick G Moeller

    $10,241.51 across 4 reported transactions

  2. 2

    Patricia Mucci Lo Russo

    $7,276.56 across 9 reported transactions

  3. 3

    Gyongyi Szabo

    $5,248.68 across 1 reported transactions

  4. 4

    Bernd Schnabl

    $4,939.63 across 1 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Spend vs. Concentration

Boehringer Ingelheim Pharma GmbH & Co.KG's spend rank (#413 of 1,925, top 21% by spend) and concentration rank (#611 of 1,838, top 33% most concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.

01.32.63.95.32691.82709.427272744.62762.2Total payments ($M)Concentration (HHI, 0-10,000)
Boehringer Ingelheim Pharma GmbH & Co.KG (highlighted) among its 12 nearest HHI-concentration neighbors, Program Year 2024. Dashed lines mark this neighborhood's median payment total and median HHI. Hover a point for the company name. Source: company_concentration (CMS Open Payments general-payment recipients).
View all 12 companies in this HHI neighborhood as a list

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Boehringer Ingelheim Pharma GmbH & Co.KG's, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Boehringer Ingelheim Pharma GmbH & Co.KG.

3NT Medical

HHI 2735

Carter Bloodcare

HHI 2730

Hyperfine Operations, Inc.

HHI 2743

Carbofix Orthopedics Inc

HHI 2743

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Boehringer Ingelheim Pharma GmbH & Co.KG.

Showing 6 of 1,924 companies with CMS-reported payment data.

Put this to use

Boehringer Ingelheim Pharma GmbH & Co.KG ranks #413 of 1,925 by all-tracks total payments, led by "Travel and Lodging".

Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Boehringer Ingelheim Pharma GmbH & Co.KG's data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.